NCT04395989 2023-12-22
FUTURE-SUPER
Fudan University
Phase 2 Unknown
Clinical Trials
9 trialsNCT06146985 2023-11-28
Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
Ruijin Hospital
Phase 2 Unknown
NCT04733417 2023-04-13
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05051865 2022-11-17
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT03827837 2022-07-01
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04129996 2022-01-11
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Fudan University
Phase 2 Unknown
NCT04866381 2021-04-29
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02336724 2018-04-17
A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown